Comparative in vitro activity of tigecycline against aerobic and facultative isolates recovered from hospitalized patients: An Argentinean multicenter study

Journal of Chemotherapy

Volumn 19, Issue 5, 2007, Pages 482-487

  Casellas, José Maria ^a,b,m   Bantar, C ^c   Duret, F ^d   D'Andrea, Elena ^e   Famiglietti, Angela ^f   Canigia, Liliana Fernández ^g   Marín, Marcelo ^h   Smayevsky, Jorgelina ⁱ   Tokumoto, Marta ^j   Tomé, Gabriela ^a   Vilaró, Mario ^k   Mobilia, Liliana ^l  

^a Centro Estudios en Antimicrobianos   (Argentina)

^b CIBIC   (Argentina)

^c Hospital General San Martín Paraná   (Argentina)

^d Medical Department   (Argentina)

^e Microbiology Department   (Argentina)

^f UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^g HOSPITAL ALEMÁN   (Argentina)

^h Fundacion Centro de Estudios Infectologicos   (Argentina)

ⁱ CEMIC   (Argentina)

^j HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^k HOSPITAL PRIVADO   (Argentina)

^l HOSPITAL SAN MARTÍN   (Argentina)

^m NONE   (Argentina)

more..

Author keywords

Antimicrobial resistance; Argentina; Tigecycline

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ACINETOBACTER; ARGENTINA; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; ENTEROBACTER; ENTEROCOCCUS; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE TYPE A; HOSPITAL PATIENT; IN VITRO STUDY; KLEBSIELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS; SERRATIA;

EID: 36549046998     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.5.482     Document Type: Article

References (27)

1. Surn PE. Peterson P. Synthesis and structure-activity relation of novel glycylcycline derivatives leading to the discovery of GAR-936 biorganisms. Med Chem Letter 1999; 17: 1459-1462.
2. Bauer G, Berens C, Projan SJ, Hillen W . Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulphate and drug-directed Fe2+ cleavage of 16S rRNA. J Antimicrob Chemother 2004; 53: 592-599.
3. Bergeron J, Ammirati M, Danley D, James L, Noreira M, Retsema J, et al. Glycylcyclines bind to the high-affinity tetracycline ribosomal binding site and evade Tet (M). and Tet (O)-mediated ribosomal protection. Antimicrob Agents Chemother 1996; 40: 2226-2228.
4. Betriú C, Rodriguez-A vial I, Sánchez BA, Gómez M, Alvarez J, Picazo JJ . In vitro activities of tigecycline (GAR-936) against recently isolated clinical bacteria in Spain. Antimicrob Agents Chemother 2004; 46: 892-895.
5. Fritsche TR, Kirby J, Jones RN. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and Gram-positive cutaneous infections. Diagn Microb Infect Dis 2004; 49: 201-209.
6. Deshpande LM, Gales AC, Jones RN. GAR-936 (9-t-butylglycylamino- minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoea. Int J Antimicrob Agents 2001; 18: 29-35.
7. Bradford P, Peterson PJ. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005; 41: 315-332.
8. Biedenbach DJ, Beach ML, Jones RN. In vitro antimicrobial activity of GAR-936 tested against antibiotic resistant gram-positive blood stream infection isolates and strains producing extended-spectrum beta lactamases. Diagn Microbiol Infect Dis 2001; 40: 173-177.
9. Gales SC, Jones RN. Antimicrobial activity and spectrum of the new glycylcycline, GAR-936, tested against 1,203 recent clinical bacterial isolates. Diag Microbiol Infect Dis 2000; 36: 19-3.
10. Goldstein EJ, Citron DM, Merriam CV, Warren Y, Terreyl K. Comparative in vitro activities of GAR - 936 against aerobic and anaerobic animal and human wound pathogens. Antimicrobial Agents Chemother 2004; 44:2747-2751.
11. rd ed. Washington, DC: ASM Press. 2004.
12. th ed. Approved standard M7-A7.Clinical Laboratory Standards Institute, Wayne, Pa. 2006.
13. Bradford PA. Tigecycline: A first in class glycylcycline. Clin Microbiol Newslett 2004; 26:153-155.
14. th informational supplement CLSI document M100-S16.Clinical and Laboratory Standards Institute, Wayne, Pa. 2006.
15. Meagher A, Ambrose P, Grasela T, Ellis-Grosse E. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis 2005;41: 333-340.
16. Peterson P, Labthavikul P, Jones HC, Bradford P. In vitro antibacterial activities of tigecycline in combination with other antimicrobial agents determined by chequerboard and time-kill kinetic analysis. J Antimicrob Chemother 2006; 57: 573-576.
17. th ICAAC. Abst. K-1522. Washington, DC 2006.
18. th ICAAC. Abst. E-722. Washington DC 2006.
19. th ICAAC. Abst. E-734. Washington, DC 2006.
20. th ICAAC. Abst. E-735. Washington DC, 2006.
21. Gales A, Jones RN, Andrade S, Pereira A, Sader H. In vitro activity of tigecycline, a new glycylcycline, tested against 1.326 clinical bacterial strains isolated from Latin America. Brazil J Infect Dis 2005; 5: 348-356.
22. Casellas JM, Tome G, Bantar C, et al. Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin- tazobactam against selected bacterial isolates from hospitalized patients. Diag Microbiol Infect Dis 2003; 47 (3): 527-37.
23. Agwult KN, MacGowan R. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 2006; 58: 256-265.
24. Jones RN, Ferraro MJ, Heller B, Shreckenberger P, Swenson J, Sader HS. Multicenter studies of tigecycline disk diffusion susceptibility. Results for Acinetobacter spp. J Clin Microbiol 2007; 45:227-230.
25. Breedt J, Teras J, Gardovskis J, Maritz F, Vaasna T, Roos D et al. Safety and efficacy of tigecycline in treatment of skin and skin-structure infections: results of a double-blind phase 3 comparative study with vancomycin-aztreonam. Antimicrobial Agents Chemother 2005;49: 4658-4666.
26. Grosse-Ellis E, Babinchak T, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin structure infections. Clin InfecT Dis 2005; 41: 341-353.
27. Babinchak T, Ellis-Grosse E, Dartois N, Rose G, Loh E. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005;41: 354-367.